Welcome to our dedicated page for Iridex SEC filings (Ticker: IRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Want to know how sales of MicroPulse® laser consoles are trending or whether insiders are buying stock before new clinical data? This Iridex SEC filings hub starts where most ophthalmology investors begin—searching for hard-to-find data hidden in 10-Ks and 10-Qs. From cash flow tied to disposable probe sales to FDA-related 8-K disclosures, every document is organized and tagged so you can stop hunting and start analyzing.
Use Stock Titan’s AI to move straight to answers. Our algorithms deliver Iridex SEC filings explained simply: instant highlights of revenue by product line, flags on R&D spending changes, and side-by-side Iridex earnings report filing analysis. Need quick transaction intel? Receive Iridex Form 4 insider transactions real-time alerts that clarify Iridex executive stock transactions Form 4 in plain language. Each link opens the original EDGAR text plus an AI summary that answers common queries like “How did gross margin shift this quarter?” or “Which directors exercised options?”
- 10-K: The Iridex annual report 10-K simplified pinpoints consumable vs. console revenue and global distributor performance.
- 10-Q: Read the latest Iridex quarterly earnings report 10-Q filing with AI-generated trend notes.
- Form 4: Track Iridex insider trading Form 4 transactions moments after they post.
- 8-K: Critical announcements—Iridex 8-K material events explained without jargon.
- DEF 14A: The Iridex proxy statement executive compensation section highlights incentive alignment with glaucoma therapy milestones.
Whether you’re understanding Iridex SEC documents with AI for the first time or comparing quarter-over-quarter adoption of retina lasers, our real-time feed and concise commentary turn dense filings into actionable insights.
IRIDEX Corporation director reports open-market stock purchase
A director of IRIDEX Corporation reported buying 2,000 shares of common stock on 12/16/2025 at a price of $1.0099 per share. After this transaction, the director beneficially owns 251,550 shares directly and 69,300 shares indirectly through a spouse. An additional 81,150 shares are held indirectly through the William M. Moore Trust and the Patricia A. Moore Trust, which hold the shares as tenants in common under trust agreements dated August 16, 2016 and August 17, 2016, respectively.
IRIDEX director William M. Moore reported buying 20,000 shares of IRIDEX common stock on 12/15/2025, shown as a purchase transaction.
The shares were acquired in multiple trades at weighted average prices between $0.98 and $0.9885 per share. Following this transaction, Moore directly owned 249,550 IRIDEX shares, with an additional 69,300 shares held indirectly by his spouse and 81,150 shares held indirectly through the William M. Moore Trust and the Patricia A. Moore Trust as tenants in common.
Iridex Corp director reported buying additional company common stock in December 2025. On December 11, 2025, the director purchased 9,080 shares at a weighted average price between
The report also discloses indirect holdings of 69,300 shares held by the director’s spouse and 30,026 shares held through the William M. Moore Trust and the Patricia A. Moore Trust as tenants in common.
IRIDEX Corp's chief financial officer, Romeo R. Dizon, reported acquiring 2,365 shares of common stock on 12/12/2025 at $0.9709 per share. Following this purchase, his direct ownership increased to 92,685 IRIDEX common shares, as disclosed in the Form 4 insider transaction report.
IRIDEX Corporation filed a current report to highlight its participation in the Sidoti Year-End Virtual Investor Conference on December 11, 2025. A live webcast of the presentation is scheduled to begin at 10:45 a.m. Eastern Time and will be available, along with an archived version, in the investors section of the company’s website at www.IRIDEX.com.
The company is also making available a set of presentation materials as Exhibit 99.1. These materials are being furnished, not filed, under Regulation FD, meaning they are shared for information purposes and are not treated as part of the company’s formal financial reporting under Section 18 of the Exchange Act.
IRIDEX CORP reported that its Chief Financial Officer, Romeo R. Dizon, bought additional company stock. On 11/20/2025, he acquired 5,760 shares of common stock in an open market purchase at a price of $0.96 per share. After this transaction, he beneficially owned 88,736 shares of IRIDEX common stock directly.
IRIDEX Corporation (IRIX) reported an insider share purchase by its Chief Financial Officer, Romeo R. Dizon. On 11/19/2025, the CFO bought 1,000 shares of common stock at $0.96 per share in an open-market purchase, bringing his directly owned holdings to 82,976 shares. This activity was reported on a Form 4 filed for a single reporting person.
IRIDEX Corp's Chief Financial Officer, Romeo R. Dizon, reported an open-market purchase of company stock. On 11/18/2025, he bought 2,133 shares of IRIDEX common stock at a price of $0.94 per share, as shown in Table I of the filing. After this transaction, he beneficially owned 81,976 shares of IRIDEX common stock in direct ownership. This report was filed as a Form 4 by a single reporting person, indicating a change in his personal holdings of IRIDEX equity.
IRIDEX Corporation (IRIX) director share purchases disclosed. A company director reported open-market purchases of common stock in two transactions. On 11/14/2025, the director bought 28,157 shares at a weighted average price of $0.9676 per share, in multiple trades between $0.9367 and $0.98. On 11/17/2025, the director bought 21,843 shares at a weighted average price of $0.9654 per share, in multiple trades between $0.95 and $0.98.
After these transactions, the director beneficially owns 250,674 shares directly. In addition, 69,300 shares are held indirectly by the director’s spouse, and 30,026 shares are held indirectly through trusts identified in the footnotes. The filing notes that detailed trade‑by‑trade pricing information is available upon request.
IRIDEX CORP (IRIX)11/17/2025, the reporting person bought 3,034 shares of common stock at a price of $0.96 per share and an additional 90 shares at $0.9569 per share in open-market transactions coded as purchases ("P").
Following these transactions, the reporting person beneficially owns 79,843 shares of IRIDEX common stock, held directly. The filing indicates that it is made by one reporting person and confirms the officer status as Chief Financial Officer.
FAQ
What is the current stock price of Iridex (IRIX)?
What is the market cap of Iridex (IRIX)?
